Korean Government Shifts Attention To CRO Sector In Steady Drive To Build Up Biotech Infrastructure, Biosimilars
This article was originally published in PharmAsia News
Executive Summary
SEOUL - After realizing that it was a late comer, the Korean government is now moving to strengthen its local CRO industry to support a clinical trial infrastructure that is bursting at the seams as MNCs flock to Korea to conduct early-stage trials
You may also be interested in...
Quintiles Asia Strategic Planning Director Simranjit Singh On Korea’s Clinical Trial Strategy: An Interview With PharmAsia News
The CRO exec discusses Korea’s expanding role in global clinical trials and the rising interest among MNCs for conducting trials in Korea, as evidenced by Pfizer’s Xalkori.
Korea FDA To Consider Substantial Reduction To IND Timeframe
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.
Korea FDA To Consider Substantial Reduction To IND Timeframe
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.